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Abstract
Background: ATP-binding cassette transporters at the blood-brain barrier are actively regulated upon ischemic
stroke in a way that impedes the access of pharmacological compounds to the brain tissue. The luminal
endothelial transporter ABCB1 was recently shown to be increased, whereas the abluminal transporter ABCC1 was
decreased on ischemic brain capillaries. In vitro studies using epithelial cells suggested that ABCB1 is regulated
during hypoxia in a hypoxia-inducible factor (HIF)-1a-dependent way.
Methods: In order to investigate whether hypoxia might be responsible for the expression changes of ABCB1 and
ABCC1 in the ischemic brain, the immortalised human brain microvascular endothelial cell line hCMEC/D3 was
exposed to hypoxia (1%) or anoxia (0%). Cell lysates were analysed by Western blot to detect the protein
expression of ABCB1, ABCC1, HIF-1a and HIF-2a.
Results: During hypoxia, an accumulation of HIF-1a and HIF-2a was noticed in hCMEC/D3 cells that followed
different time kinetics. Both HIF-1a and HIF-2a abundance increased within 4 h of hypoxia. HIF-1a levels
decreased to below detection levels within 16 h of hypoxia, whereas HIF-2a remained elevated even after 48 h. No
changes of ABCB1 and ABCC1 expression were detected, neither on the mRNA nor protein level.
Conclusion: Our data suggests that other factors than hypoxia may be responsible for the expression changes of
ATP-binding cassette transporters in the ischemic brain.
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Background
ATP-binding cassette (ABC) transporters are efflux pro-
t e i n st h a ta r ea b u n d a n t l ye x p r e s s e da tt h eb l o o d - b r a i n
barrier [1,2]. ABC transporters protect the brain from
t o x i cc o m p o u n d s ,b u ta tt h es a m et i m et h e yp r e v e n tt h e
access of drugs into the brain [1,2]. In brain disease,
changes of ABC transporter expression and hence func-
tion have been demonstrated to modulate barrier proper-
ties [2]. Upon ischemia, ABC transporters are regulated
on brain capillary endothelial cells in a coordinated way
that impedes the delivery of drugs into the brain. As
such, the luminal transporter ABCB1, which transfers its
substrates from the brain into the blood, was increased
[3], whereas the abluminal transporter ABCC1, which
carries its substrates in the opposite direction, i.e. from
blood to brain was decreased [4] following middle cere-
bral artery occlusion (MCAO) in mice. The altered abun-
dance had a major impact on the biodistribution of drugs
in the brain and resulted in a poorer delivery of neuro-
protective drugs to the post-ischaemic brain, despite a
stroke-related impairment of blood-brain barrier integrity
[3,4].
Understanding the regulatory mechanisms of the lumi-
nal to abluminal ABC transporter balance is an impor-
tant challenge for brain pharmacology, as it may identify
strategies that improve the access of drugs to the brain.
Interestingly, the expression of ABCB1 has previously
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hypoxia-inducible factor (HIF)-1a-dependent way [5].
Since hypoxia is a major factor contributing to ischemic
injury, we were intrigued by the question whether HIF-
1a-dependent signaling is also responsible for the ische-
mia-induced expression changes of ABC transporters in
endothelial cells. To elucidate this issue, we exposed the
cells of the immortalised human brain microvascular
endothelial cell line hCMEC/D3 to conditions of ambient
hypoxia.
Methods
Cell culture
hCMEC/D3 cells were propagated in Microvascular
Endothelial Cell Medium-2 (EGM-2MV; obtained from
Lonza, Allendale, NJ, U.S.A.) [6]. Cells from passage 25 to
35 were grown on surfaces coated with 100 μg/ml rat tail
collagen type-I (BD Biosciences, Heidelberg, Germany).
Cells were plated on collagen-coated 60 mm dishes and
placed in a hypoxia chamber (oxygen concentration: 1%).
In additional studies, HIF-1a was chemically induced by
supplementing the cells with the iron chelator deferoxa-
mine mesylate (DFO) (0.1 mM; Sigma-Aldrich, Deisenho-
fen, Germany) or the prolyl-4 hydroxylase inhibitor
dimethyloxaloyl glycine (DMOG) (1 mM; Alexis Biochem-
icals, Lörrach, Germany). To generate oxygen concentra-
tions close to anoxia, cells were furthermore incubated in
GasPak (BBL) anoxic jars using BD GasPak EZ anoxic
container systems (BD Diagnostic Systems, Heidelberg,
Germany). The duration of hypoxia or anoxia exposure is
specified below. All experiments were performed at least
three times.
Antibodies
The monoclonal antibody against human HIF-1a (610959)
was purchased from BD Biosciences (Heidelberg, Ger-
many). The polyclonal antibody against HIF-2a (AF 2886)
was from R&D Systems (Wiesbaden-Nordenstadt, Ger-
many). The polyclonal antibody against ABCB1 (sc-8313)
was from Santa Cruz Biotechnology (Santa Cruz, CA, U.S.
A.) and the monoclonal antibody against ABCC1 was pur-
chased from Alexis Biochemicals (Lörrach, Germany). The
polyclonal antibody against actin (A2103) was from
Sigma-Aldrich. The goat polyclonal, horse radish peroxi-
dase (HRP)-conjugated antibodies raised against rabbit
(PO448) and mouse (PO447) IgG were purchased from
DAKO (Hamburg, Germany).
Western blots
Western blotting for ABCB1 and ABCC1 was performed
as described previously [7]. Briefly, cell lysates were pre-
pared using RIPA lysis buffer (50 mM Tris pH 7.5, 0.1%
SDS, 1% Nonidet P40, 0.5% sodium deoxycholate, 2 mM
EDTA, 150 mM NaCl) containing protease inhibitor
cocktail (Roche, Mannheim, Germany). Protein samples
were separated on 7.5% reducing SDS gels and blotted
onto PVDF membranes. After the transfer, blocking of
unspecific binding sites was achieved by incubation in
Tris-buffered saline (50 mM Tris/HCl, 150 mM NaCl)
containing 0.5% Tween 20 (TBST, pH 7.2) and 5%
skimmed milk. Washed membranes were incubated over-
night at 4°C with antibody against ABCB1 (1:1000 in
TBST) or ABCC1 (1:200 in TBST) and for 2 h at 20°C
with antibody against HIF-1a (1:1000 in TBST) and HIF-
2a (1:1000 in TBST). Following incubation with HRP-
conjugated secondary antibodies, the target proteins were
detected with the enhanced chemoluminescence (ECL)
kit (GE Healthcare, Munich, Germany) using an FX7
chemoluminescence documentation system (Peqlab,
Erlangen, Germany).
Real time quantitative PCR (rt-PCR)
Total RNA was extracted from hCMEC/D3 cells with
RNeasy Midi Kit (Qiagen, Hilden, Germany) according to
manufacturer’sp r o t o c o l .1μg RNA was reverse-tran-
scribed to cDNA. The following abcb1 and abcc1 primers
were used: abcb1 (84 bp): 5’, AAA TTG GCT TGA CAA
GTT GTA TAT GG; 3’, CAC CAG CAT CAT GAG
AGG AAG TC; abcc1 (139 bp): 5’,T C TA C CT C CT G T
GGC TGA ATC TG; 3’, CCG ATT GTC TTT GCT CTT
CAT G. In our studies, succinate dehydrogenase (sdha)
was analysed as housekeeping gene using primers provided
by Qiagen (cat.-no.: QT00059486). Abcb1, abcc1 and sdha
mRNA expression was analysed using SYBR
® green as
fluorescent dye (Eurogentec, Verviers, Belgium) on the
Step One Plus Real Time PCR Detection System (Applied
Biosystems, Darmstadt, Germany) in a two-step rt-PCR.
The denaturation steps were performed at 95°C for 10
min followed by 40 cycles at 95°C for 15 s, and at 60°C for
1 min. Rt-PCR was always performed in duplicates, for
which mean values were determined. Amounts of cDNA
were normalized to sdha using the Δct method, as pre-
viously described [7].
Results
HIF-1a and HIF-2a expression in hCMEC/D3 cell line
during normoxia and hypoxia
To eludicate the impact of cell confluency on hypoxia-
inducible expression of HIF-1a and HIF-2a, cells seeded
at different densities were exposed to 1% oxygen for 6
hours and compared with control cells that were simulta-
neously kept under normoxia with or without the addition
of 0.1 mM DFO. Western blot analysis revealed that
whereas no HIF-1a and HIF-2a protein was detectable in
control cells under normoxia, both hypoxia and DFO
induced HIF-1a and HIF-2a accumulation in hCMEC/D3
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Page 2 of 6cells (Figure 1A, B). Interestingly, HIF-1a and HIF-2a
abundance changed with confluency state. As such, both
the basal and hypoxic expression of both proteins signifi-
cantly increased with increasing cell density (Figure 1A, B).
Kinetics of HIF-1a and HIF-2a expression in hCMEC/D3
during hypoxia
To evaluate the kinetics of hypoxic induction of HIF-1a
and HIF-2a, hCMEC/D3 cells were exposed to different
durations of hypoxia. Western blot analysis revealed that
both proteins were increased when cells were exposed
to 1% oxygen for 4 h (Figure 2A, B). Interestingly, HIF-
2a levels continuously remained elevated after 24 and
48 h hypoxia (Figure 2B). In contrast, HIF-1a had
declined again after 24 h of oxygen deprivation (Figure
2A). Cells exposed to 1 mM DMOG or 0.1 mM DFO
for 4 h served as positive controls.
ABCB1 and ABCC1 expression remains unchanged in
hCMEC/D3 cells during hypoxia and anoxia
Cells exposed to 4 to 48 h hypoxia or 4 h anoxia were
evaluated by Western blot analysis [7] for changes in
the abundance of the ABCB1 and ABCC1 protein. In
addition, cells exposed to 4 h hypoxia were assessed by
rt-PCR for changes in abcb1 and abcc1 mRNA expres-
sion. In none of the experimental conditions examined,
changes in ABCB1 or ABCC1 protein or abcb1 and
abcc1 mRNA levels were found (Figures 3 and 4).
Discussion
We report that ABC transporters are not regulated by
hypoxia in the immortalised human brain microvascular
endothelial cell line hCMEC/D3, which provides a unique
and accessible in vitro system to study protein responses
during sustained oxygen deprivation [6]. Our interest was
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Figure 1 Hypoxia-inducible accumulation of HIF-1a and HIF-2a in hCMEC/D3 cells depends on confluency state. Cells were exposed to
normoxia (21% oxygen) or hypoxia (1% oxygen) for 6 hours. For chemical HIF-1a and HIF-2a induction, normoxic cells were treated with 0.1
mM of the iron chelator deferoxamine mesylate (DFO). HIF-1a and HIF-2a abundance was examined using Western blot analysis.
A 
O  2 (%)     21%   21%  1%   21%   1% 
actin 
HIF 2α 
actin 
O  2 (%) 
4h  24h 48h  4h  24h 48h 
21%  1% 
actin 
O  2 (%) 
4h  24h 48h 
21%  1%  DFO 
4h 24h 
O  2 (%)     21%   21%  1%   21%   1% 
actin  actin 
O  2 (%) 
4h  24h 48h 
21%  1% 
actin 
O  2 (%) 
4h  24h 48h 
21%  1%  DFO 
4h  A B 
O  2 (%)     21%   21%  1%   21%   1% 
actin  actin 
O  2 (%) 
4h  24h 48h 
21%  1% 
actin 
O  2 (%) 
4h  24h 48h 
21%  1%  DFO 
4h 
O  2 (%)     21%   21%  1%   21%   1% 
HIF 1α 
actin  actin 
O  2 (%) 
4h  24h 48h 
21%  1% 
actin 
O  2 (%) 
4h  24h 48h 
21%  1%  DFO 
4h  B 
Figure 2 HIF-1a is transiently induced whereas HIF-2a is continuously elevated in hypoxic hCMEC/D3 cells. Cells were exposed to
normoxia (21% oxygen) or hypoxia (1%) for various hours. For chemical HIF-1a and HIF-2a induction, 0.1 mM of DFO or 1 mM of the prolyl-4
hydroxylase inhibitor dimethyloxaloyl glycine (DMOG) for 4 h were administered. HIF-1a and HIF-2a abundance was assessed by Western blot
analysis.
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Page 3 of 6sparked by in vivo studies in a model of MCAO that
demonstrated an increase of ABCB1 [3] and a decrease
of ABCC1 [4] protein levels on the surface of ischemic
cerebral microvessels. Studies in the epithelial cell lines
OKF6, T84 and Caco-2 had shown that the ABCB1
transporter was regulated in a HIF-1a-dependent way
upon hypoxia [5]. Thus, we hypothesized that ABCB1
expression in human brain microvascular endothelial
cells may also be enhanced as a consequence of HIF
activation.
In our study, both HIF-1a and HIF-2a were found to
be induced upon hypoxia. While HIF-2a exhibited a
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Figure 3 ABCB1 and ABCC1 abundance is not influenced by hypoxia or anoxia in hCMEC/D3 cells. Cells were exposed to normoxia (21%
oxygen), hypoxia (1%) or anoxia (0%, in A) for 4 to 48 hours. The abundance of ABCB1 and ABCC1 protein was evaluated by Western blot
analysis. As positive control, cells exposed to the prolyl-4 hydroxylase inhibitor dimethyloxaloyl glycine (DMOG) were assessed (in B). Note the
absence of expression changes at any of the time points examined (in A-C).
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Page 4 of 6long-lasting accumulation in the brain endothelial cell
line, HIF-1a levels were only transiently increased.
While HIF-1a is known to be expressed in virtually all
tissues, HIF-2a has been shown to be restricted to cer-
tain cell types including endothelial cells, cells of the
kidney, liver, lungs and pancreas [8]. However, no
changes in ABCB1 or ABCC1 protein levels were
detected in our present study, despite a strong induction
of HIF-1a and HIF-2a in the hCMEC/D3 cells, suggest-
ing that HIF might not be essential for ABC transporter
regulation in cerebral microvessels. The regulation of
both transporters seen in cerebral ischaemia could
depend on other factors than hypoxia alone that go
hand in hand with ischaemia and have been described
to induce ABCB1 expression, such as glucose depletion
[9] or reactive oxygen species that are generated by
reoxygenation as shown in rat brain endothelial cells
[10,11].
To our knowledge only three other studies have so far
examined the effect of hypoxia on ABC transporters in
brain endothelial cells. In a primary rat brain endothelial
cell model of hypoxia/reoxygenation, either induced by
hydrogen peroxide administration or by reoxygenation
following 6 hours of sustained hypoxia, Felix and Barrand
[10] showed increased levels of ABCB1 6 hours following
hypoxia and then again 24 hours following reoxygena-
tion. Robertson et al. [11] studied the expression of
ABCB1 in primary and immortalised rat brain endothelial
cells that underwent hypoxia/reoxygenation. Exposure of
primary rat brain endothelial cells to 6 hours of hypoxia
alone revealed no changes in ABCB1 protein levels com-
pared to normoxic controls. Significant increases in
ABCB1 levels were only observed 24 h after 6 h hypoxia
with reoxygenation. Xiao-Dong et al. [12] observed that
repetitive hypoxia/reoxygenation may induce an up-regu-
lation of ABCB1 in cultured rat brain microvascular
endothelial cells. In that study, cells underwent hypoxia
by covering the cells with paraffin oil once daily for 15
min over a time period of 8 days. None of the authors so
far investigated the effect of over-night exposure to
hypoxia on ABCB1 levels.
We did not investigate reoxygenation conditions in the
present study, since we were interested in the role of
HIF-1a and HIF-2a in the regulation of ABC transpor-
ters. Neither did we investigate ABC transporter expres-
sion in co-culture with human astrocytes that are known
to have a regulatory function at the blood-brain barrier
[13]. Based on the data presented here, it seems that the
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Figure 4 ABCB1 and ABCC1 expression is not influenced by hypoxia on the protein and mRNA level. Cells were exposed to normoxia
(21% oxygen) or hypoxia (1%). The abundance of ABCB1 and ABCC1 protein was examined by Western blot analysis after 16 h (in A), whereas
abcb1 and abcc1 mRNA levels were analysed by rt-PCR after 4 h exposure (in B). Data are means ± SD values. Results from four (in A) or three
(in B) different experiments are shown. Rt-PCR data were normalised to sdha that was evaluated as housekeeping gene.
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Page 5 of 6responses of ABC transporters to hypoxia are less distinct
than previously presumed. This is underlined by recent
observations in prostate carcinoma cells, showing that
the protein expression of ABCB1 and ABCC1 were inde-
pendent of tissue oxygen levels [14]. Our results support
the idea that the mechanisms controlling the expression
of ABCB1 and ABCC1 are cell specific. Thus, hypoxia
does not seem to play a major role in the regulation of
ABC transporters in cerebral microvessels.
Conclusion
This is the first study examining the expression of HIF
and ABC transporters under sustained hypoxia in a
human cell model of the blood-brain barrier. Despite a
strong induction of HIF-1a and HIF-2a, this study did
not detect a regulation of the transporters ABCB1 and
ABCC1, indicating that neurovascular signals other than
HIF-1a and HIF-2a are responsible for the expression
changes of ABC transporters after MCAO.
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